Euro Oncology Summit October 18-19, 2018 | Amsterdam, Netherlands

Biography:

Yoshiaki Omura received Oncological Residency training at Cancer Institute of Columbia University & Doctor of Science Degree through research on Pharmaco-Electro-Physiology of Single Cardiac Cells in-vivo and in-vitro from Columbia Uni.. He researched EMF Resonance phenomenon between 2 identical molecules for non-invasive detection of molecules, at Graduate Experimental Physics Dept., Columbia Uni., for which he received U.S. patent. He is also the  creator of Bi-Digital O-Ring Test. He published over 270 original research articles, many chapters, & 9 books. He is currently Adjunct Prof. of Family & Community Medicine, New York Medical College; President & Prof. of Int’l College of Acupuncture & Electro-Therapeutics, NY; Formerly, he was also Adjunct Prof. or Visiting Prof. in Universities in USA, France, Italy, Ukraine, Japan, Korea & China. 

Abstract:

In order to make non-invasive, safe, effective, rapid screening & diagnosis of various cancers, the author developed following 3 new methods of screening & diagnosis. 1) Visible & invisible abnormalities appearing on accurate organ representation areas of face including: 1A) Visible Abnormalities include “formation of deep crease(s)”, “pigmentation”, and “protrusion” of specific organ representation areas of face, significant disappearance of hair at different organ representation areas of eyebrows; 1B) Invisible Abnormalities appearing at “Upper & Lower Lips”, “Breast representation areas” & “Alars of nose” of face & entire hands. 2) “Mouth, Hand, & Foot Writing Form” can often be used for diagnosing various cancers & their metastases without any medical knowledge of patient. 3) Detection of various cancers from rapidly changing QRS Complex of ECGs. Condition of development of cancer was evaluated using Integrin α₅β₁ or Oncogene C-fos Ab2 and aggressiveness of cancer was evaluated by non-invasively & quickly measuring 8-OH-dG which is proportional to DNA mutation & is essential to development of malignancy. 8-OH-dG increases every time cancer is metastasized. Once diagnosis is confirmed by standard lab tests or strong electromagnetic field (EMF) resonance phenomenon between 2 identical molecules or cancers using Bi-Digital O-Ring Test (which received US Patent in 1993 for diagnosis) was detected with specific cancer tissue slide, following individualized, safe, effective treatment was given: 1) individualized optimal dose of Vitamin D₃ (based on 10 unique, beneficial effects), 2) “Selective Drug Uptake Enhancement Method”, 3) 50 manual stimulations of Thymus gland representation area of back of hand (which we discovered in late 2017 and these manual stimulations increased Thymosin α₁ & Thymosin β₄ very significantly). Using this non-invasive, safe, effective treatment, even patients considered terminal, hopeless by major university cancer hospitals often improved significantly. These combined treatments were given every 8 hours. The latter 2 methods were given additional 2 or 3 times in advanced terminal cancer patients.

Biography:

Changchun Du earned MD from YanBian University Medical School in China. Following the 3 year resident training in the area of infectious diseases at Beihua University Medical School he went on to the US, and he has been doing research in biotechnology since 1996. His expertise is in hematology/oncology and cancer immunology, he has been employed as senior scientific researcher with Genentech for the past 14 years and published 16 papers in highly cited journals.    

Abstract:

One of the mechanisms that tumors evade immune surveillance is the shedding of major histocompatibility complex (MHC) class I chain–related sequence A (MICA) and MICB from the tumor cell surface. MICA/B are ligands for the activating receptor NKG2D on NK and CD8⁺ T cells. MICA/B shedding reduces cell surface MICA/B and impairs NKG2D recognition. Shed MICA/B can also mask NKG2D receptor compromising the immune surveillance activity of NK cells.

Our study shows that soluble MICA (sMICA) suppressed human NK cell cytolytic activity in vitro. The NK suppression was not due to the down-regulation of cell surface NKG2D. In the presence of MICA α3 domain-specific antibody, sMICA-mediated suppression was completely blocked and NK cell cytolytic activity was restored. In contrast, restoration effect was not observed when Fc effectorless mutant antibody was employed. Furthermore, MICA immune complex pre-formed with α3 domain-specific antibody (with wild type Fc) induced significant IFN-γ secretion by NK cells in the absence of tumor cells whereas MICA immune complex pre-formed Fc effectorless antibody failed to induce IFN-γ secretion.

Our results demonstrate that MICA α3 domain-specific antibody can overcome sMICA-mediated suppression of NK cytolytic activity. Furthermore, our data suggest that the MICA immune complex formed with α3-specific antibody can activate NKG2D receptor and restore NK cell function in Fc-dependent manner.  The clinical utility of α3 domain-specific MICA/B antibody may hold great promise for immunotherapy of tumors that express and shed MICA/B.

Biography:

Dr Ola A.Harb has completed her  PhD from Zagazig University, Zagazig, Egypt. He is the Head of the department of Ptahology, Faculty of medicine. He has published more than 30 papers in reputed journals and has been attend more than 20 conference as a speaker

Abstract:

Background;

Stem cell factor (SCF) is an inflammatory cytokine that specific to the c-KIT receptor which is a tyrosine kinase receptor belonging to the type III receptor tyrosine kinase (RTK) family. COXs are key enzymes responsible for the production of prostaglandins from arachidonic acid.

The aim of our study; is to investigate the prognostic and clinic-pathological significance of SCF and COX-2 expression in prostatic adenocarcinoma and in chronic Prostatitis a trial to emphasize association between chronic prostatitis a risk factor for cancer progression.

Methods: SCF and COX-2 expression were evaluated in tissue biopsies that are retrieved from 50 cases of prostatic adenocarcinoma, 20 cases of chronic prostatitis and 10 cases of nodular prostatic hyperplasia using immunohistochemistry, patients that were followed up for 5 years. The relationship between their levels of expressions, clinicopathological follow up and prognostic criteria were studied.

Results: SCF expression in PC was positively correlated with Advanced patient age (p=<0.001) , high level of PSA (p=0.010), higher Gleason score (p=0.011), recurrence of the tumor after successful therapy, disease free survival and overall survival (p<0.001). COX-2   expression in PC was positively correlated with Advanced patient age (p=<0.001) , high level of PSA (p=0.016), advanced D'Amico risk group (p= 0.038) higher incidence of tumor relapse, worse disease free survival and overall survival (p<0.001).

Conclusion: High levels of expression of SCF and COX-2 are associated with cancer progression and are markers of poor prognosis in PC patients.

Keywords: SCF, COX-2, prostatic adenocarcinoma, immunohistochemistry; prognosis

Biography:

Sergey Suchkov was born in the City of Astrakhan, Russia. In 1980, graduated from Astrakhan State Medical University and was awarded with MD. In 1985, maintained his PhD at the I.M. Sechenov Moscow Medical Academy and Inst of Med Enzymology. In 2001, and then his Doctor Degree at the Nat Inst of Immunology in Russia.

From 1989 through 1995, was being a Head of the Lab of Clin Immunology, Helmholtz Eye Research Inst in Moscow. From 1995 through 2004 - a Chair of the Dept for Clin Immunology, Moscow Clin Research Institute (MONIKI). In 1993-1996, was a Secretary-in-Chief of the Editorial Board, Biomedical Science, an international journal published jointly by the USSR Academy of Sciences and the Royal Society of Chemistry, UK.

At present, Dr Sergey Suchkov, MD, PhD, is:

● Professor, Director, Center for Personalized Medicine, Sechenov University and Dept of Clinical Immunology, A.I.Evdokimov Moscow State Medical and Dental University;

● Professor, Chair, Dept for Translational Medicine, Moscow Engineering Physical Institute (MEPhI), Russia

● Secretary General, United Cultural Convention (UCC), Cambridge, UK.

Dr Suchkov is a member of the:

● New York Academy of Sciences, USA

● American Chemical Society (ACS), USA;

● American Heart Association (AHA), USA;

● European Association for Medical Education (AMEE), Dundee, UK;

● EPMA (European Association for Predictive, Preventive and Personalized Medicine), Brussels, EU;

● ARVO (American Association for Research in Vision and Ophthalmology);

● ISER (International Society for Eye Research);

● Personalized Medicine Coalition (PMC), Washington, DC, USA

Dr Suchkov is a member of the Editorial Boards of “Open Journal of Immunology”, EPMA J., American J. of Cardiovascular Research and “Personalized Medicine Universe”

Abstract:

A new systems approach to diseased states and wellness result in a new branch in the healthcare services, namely, personalized and precision medicine (PPM). To achieve the implementation of PM concept, it is necessary to create a fundamentally new strategy based upon the subclinical recognition of biopredictors of hidden abnormalities long before the disease clinically manifests itself.

Each decision-maker values the impact of their decision to use PPM on their own budget and well-being, which may not necessarily be optimal for society as a whole. It would be extremely useful to integrate data harvesting from different databanks for applications such as prediction and personalization of further treatment to thus provide more tailored measures for the patients resulting in improved patient outcomes, reduced adverse events, and more cost effective use of health care resources. A lack of medical guidelines has been identified by the majority of responders as the predominant barrier for adoption, indicating a need for the development of best practices and guidelines to support the implementation of PPM!

Implementation of PPM requires a lot before the current model “physician-patient” could be gradually displaced by a new model “medical advisor-healthy person-at-risk”. This is the reason for developing global scientific, clinical, social, and educational projects in the area of PPM to elicit the content of the new branch.

Biography:

Wenjun Pu is currently a PhD student in the School of Pharmacy of The University of Queensland. Her studies mainly focus on the effect of both osmotic and hydrostatic pressure on glioblastoma invasiveness. She has developped in vitro pressure models, manipulated the expression of candidate proteins mediating the GBM response to pressure, and is testing her hypotheses using the following end points: matrix protease production in the conditioned medium, mRNA expression of proteases and EMT markers, invasion through basement membrane.  

Abstract:

Introduction. Glioblastoma (GBM) is a type of brain tumour with high invasiveness and poor prognosis. Both hydrostatic and osmotic pressures are altered in the GBM tumour microenvironment. We hypothesize that increased hydrostatic and osmotic pressures upregulate glioblastoma invasiveness. Better understanding of the molecular and cellular mechanisms linking  pressure increases to GBM invasiveness may help develop innovative therapeutic approaches.

Aims: To evaluate the effect of hydrostatic and osmotic pressure on GBM invasive potential.

Methods: The hydrostatic pressure was increased via air pressure in cell culture flasks to 30 mmHg. The osmotic pressure of GBM cell culture medium was adjusted using sodium chloride or water. Cells were incubated in serum-free medium with varying osmolality (from 260 to 440 mOsm) or under increased hydrostatic pressure (30 mmHg) for 48 hours. Cell viability was measured using the MTT assay. The proteolytic profile and epithelial-mesenchymal transition (EMT) were investigated using in-gel zymography and real-time qPCR. The EMT markers assessed were snail-1, slug, twist, vimentin and N-cadherin. Invasion was investigated in vitro using Transwell™ inserts coated with basement membrane-like protein.

Results: Raised hydrostatic pressure resulted in increased expression of urokinase-type plasminogen activator (uPA) and several EMT markers in GBM cell lines U87 and U251. In response to osmotic stress, U87 and U251 cell lines upregulated the expression of uPA and matrix metalloproteinases (MMPs) well as some of the EMT markers tested.

Discussion. Our findings suggest that GBM respond to two types of pressure stress by increasing matrix-degrading enzyme production, and adopting a gene expression phenotype reminiscent of EMT.

Biography:

Dr. Wassil Nowicky — Dipl. Ing., Dr. techn., DDDr. h. c., Director of “Nowicky Pharma” and President of the Ukrainian Anti-Cancer Institute (Vienna, Austria). Has finished his study at the Radiotechnical Faculty of the Technical University of Lviv (Ukraine) with the end of 1955 with graduation to “Diplomingeniueur” in 1960 which title was nostrificated in Austria in 1975. Dr. Wassil Nowicky became the very first scientist in the development of the anticancer protonic therapy and is the inventor of the preparation against cancer with a selective effect on basis of celandine alkaloids “NSC-631570”. He used the factor that cancer cells are more negative charged than normal cells and invented the Celandine alkaloid with a positive charge thanks to which it accumulates in cancer cells very fast. Thus, Dr. Nowicky is invited as an Honorable Speaker to take part in many scientific international congresses and conferences in USA, Australia, Japan, UAE, Europe. Author of over 300 scientific articles dedicated to cancer research. Dr. Wassil Nowicky is a real member of the New York Academy of Sciences, member of the European Union for applied immunology and of the American Association for scientific progress, honorary doctor of the Janka Kupala University in Hrodno, doctor “honoris causa” of the Open international university on complex medicine in Colombo, honorary member of the Austrian Society of a name od Albert Schweizer. He has received the award for merits of National guild of pharmasists of America. the award of Austrian Society of sanitary, hygiene and public health services and others.

Abstract:

One of the most significant problems of cancer therapy is the damaging activity of anticancer drugs against normal body cells. All attempts to develop a therapeutic agent with a selective cytotoxic effect on tumor cells had no much success because of the high degree of biological identity between healthy and malignant cells. The celandine is being used in the medicine over more than 3500 years. The first data concerning the therapeutic effect of the juice of celandine in the patient with malignant melanoma were published in Germany in 1536. From that time drugs based on biologically active substances of celandine are widely used to treat cancer and non-cancer disease. It is well known that tumor cell is more negatively charged as compared to normal cell. We have used this feature of the tumor cell to give NSC631570 a property to selectively interact with it, without endangering healthy cells and tissues. The drug is strongly positively charged. Due to this it has an ability to be selectively accumulated in tumor tissue and to induce tumor cell apoptosis only in tumor cells without harmful effect on normal cells. Potent selective antitumor effect of NSC631570 repeatedly proven by the results of clinical trials. Until now this preparation has been tested on over 100 cancer cell lines and on 12 normal cell lines and the results of the studies carried out in more than 120 universities and research centers (in particular at the National Cancer Institute (the USA)) have shown that the NSC 631570 killed only cancer cells without having damaged the normal cells what confirmed its selective effect.

Biography:

Dr. Antaya is a world-wide leader in the development of particle sources for Proton Radiotherapy and Radioisotope Generation, focusing on compact low cost local solutions that enable advanced medicine anywhere, and has been responsible for the designs of the Mevion Proton Therapy  cyclotron, the Ionetix PET isotope Cyclotron and the Pronova Superconducting Double Bend Acromat Gantry for Proton Therapy. He holds more than 25 patents in this subject matter in the US and other countries, and has published more than 50 papers in related scientific journals and conference proceedings. He is a member of IEEE, APS, AAAS, NYAS, SSP and SWB.

Abstract:

The next frontier for Proton Beam Radiotherapy (PT) is to move away from large, expensive, and costly regional and national treatment centers that are hard to justify, to truely local, low cost systems with small footprint, advanced fast high precision scanned beam treatment methods, reduced need for custom patient treatment appliances, and significantly lower ownership costs, to enable this treatment modality… anywhere on the planet. We have to do this primaily for humane reasons- people requiring such cancer tretments have families, jobs and other responsibitities, and really need to be treated near their homes.  We have to do this for equality- if you believe a treatment has beneficial characteristics, and for PT that would be lower normal tissue morbidity and lower total treatment dose, then everyone should have access to it. And we have to do this for medicine- more long baseline studies of PT versus IMRT are needed to clearly establish the efficasy of PT, and that mean more systems put in the hands of leading researcher to do those comparison studies. With these principles always in mind, we have been in the vanguard of this movement now for nearly 2 decades, and are already partially or wholely responsible for many of the current generation compact systems being used for PT, or that are about to be used for PT.  These developments have been hard earned, requiring advances in beam physics,  engineering of all types, instrumentation and controls, and serial advances in all of the associated technolgies. But we are not done, and we think that we finally have the right single room PT solution, on parity with X-ray Radiotherapy in footprint, cost and complexity, for which we plan to present the scientific and technical basis of, for critical review, to oncologists, in this talk, at this meeting.

Keywords: Proton beam Radiotherapy

Biography:

Dr. Raye Angeli B. Abella is a Bachelor of Science in Biology graduate from the University of the Philippines in the Visayas Cebu College. She completed her medical education at the West Visayas State University College of Medicine at La paz, Iloilo City, Philippines. She also earned a degree in Masters in Public Management- Major in Health Systems and Development at the Development Academy of the Philippines. She is currently a third year resident-in-training of the Department of Internal Medicine at Corazon Locsin Montelibano Memorial Regional Hospital, Bacolod City, Philippines.

Abstract:

SYNOPSIS: Colonic adenocarcinoma frequently metastasizes to the liver, lungs, and bones. Cutaneous metastasis is a rare initial manifestation of colonic adenocarcinoma. This is a case of a 45-year old male diagnosed with Colonic Adenocarcinoma, initially presenting with cutaneous metastasis.

CLINICAL SCENARIO: We report a case of a 45-year old male who came in due to the presence of a mass at the left gluteal area, noted six months prior to admission, which progressively increased in size. Pallor and weight loss were likewise present.

PHYSICAL FINDINGS: Pertinent physical examination findings revealed presence of a gray to dark brown fungating mass, approximately 10cm x 20 cm in size, at the left gluteal area extending up to the medial 3^rd of the right gluteal region, with presence of bloody discharge.

COURSE IN THE WARDS: We report a case of a 45 year-old male who presented with a gluteal mass. Initial incision biopsy done revealed findings of Papillary Eccrine Adenocarcinoma vs. Metastatic Adenocarcinoma. On further work-up, no significant findings was seen on chest radiography. Computed tomography (CT) of the abdomen showed presence of left gluteal and ischiorectal masses, retroperitoneal and mesenteric lymphadenopathies, suggestive of malignancy. Colonoscopy done revealed no significant findings. Patient underwent excision of gluteal mass with creation of gluteus maximus rotational flap. Frozen section biopsy of the mass showed a malignant neoplasm, consistent that of Adenocarcinoma, moderately-differentiated. Immunohistochemistry studies of the neoplasm show positive (+) cytoplasmic membrane staining for CK20 and negative (-) cytoplasmic membrane staining for CK7. The following immunohistochemistry are consistent with adenocarcinoma of colonic origin. The patient was then advised for chemotherapy, however, was lost to follow-up.

CONCLUSION: Cutaneous metastasis is a very rare initial manifestation of colonic adenocarcinoma. Cutaneous metastases are thought to be associated with poor average survival because of underlying widespread disease, thus physicians should be more aggressive in terms of management.

Keywords: Colonic adenocarcinoma, Metastatic adenocarcinoma, Cutaneous metastasis

Biography:

Dr. Chang Gong, MD and PhD, is currently an Associate Professor of Department of Breast Surgery, Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China. She started her clinical training and basic research career on breast cancer since 2001 and underwent her post-doctoral training in INSERM, Paris and UK. She has been involved in biomarker-based translational clinical trials on breast cancer since 2007. Dr. Chang Gong also focused on the epigenetic regulation of HDAC and non-coding RNA on drug resistance and metastasis of breast cancer. She published more than 30 papers on Cancer Cell, Nat Commun, Cancer Res, Oncogene, Autophagy, and JBC. 

Abstract:

Increasing evidence suggests circRNAs exert vital functions in tumor progression via sponging miRNAs. However, the role of circular RNAs in breast cancer remains mostly unclear. Here we reported the molecular mechanisms of a novel circRNA, hsa_circ_001783 in regulating breast cancer progression and its ability in predicting clinical outcomes by integrating high throughput computation, experimental technologies in vitro and clinical investigation. Our computational pipeline identified hsa_circ_001783 as the one with highest score out of 594 breast cancer-associated circRNA candidates. We found the circRNA was enriched in cytoplasm and overexpressed in breast tumor as compared to paired non-cancerous tissue. High expression of hsa_circ_001783 correlated with higher tumor burden (p=0.047) and poor overall survival (p=0.025) in128 patients. Knock-down of hsa_circ_001783 remarkably inhibited the proliferation and invasion of MDA-MB-231 and MDA-MB-468 cells. We found hsa_circ_001783 increased significantly by 1.5-2 folds while 7 miRNAs, predicted targets of hsa_circ_001783, were remarkably reduced (fold change>1.5) in mRNA expression levels in BT549, MDA-MB-468 and MDA-MB-231 as compared with MCF-7 breast cancer cell lines. Among all the targets, miR-200c was the one in the strongest correlation with hsa_circ_001783 in expression levels. Knockdown of hsa_circ_00178 in MDA-MB-231 breast cancer cells suppressed expression of miR-200c-targeted genes ZEB1, ZEB2 and CCNA2. The expression level of hsa_circ_001783in human breast cancer tissues negatively correlated with expression of miR-200c (p=0.0286), but positively correlated with that of ZEB1 (p=0.002), ZEB2 (p=0.0001) and CCNA2 (p=0.005).In a conclusion, hsa_circ_001783 regulates breast cancer progression via sponging miR-200c. The circRNA may serve as a novel predictor of ¬¬clinical outcomes for breast cancer.

Biography:

Dr Ola A.Harb has completed her  PhD from Zagazig University, Zagazig, Egypt. He is the Head of the department of Ptahology, Faculty of medicine. He has published more than 30 papers in reputed journals and has been attend more than 20 conference as a speaker

Abstract:

In the present study, we examined the relationship between Beclin-1 expression and HIF-1α expression in 60 cases of serous ovarian carcinoma (SOC) using immunohistochemistry.

We followed our patients for 3 years, analyzed the relationship between markers expression, clinic-pathological criteria and the prognosis of patients.

Results: the expression of Beclin-1 in SOC was significantly negatively correlated with advanced age of the patients (p=0.003), higher grade (p=0.002)& advanced stage of the tumor, presence of distant metastases (p<0.001), peritoneal implants (p=0.006), L.N metastases (p=0.004), bilaterality (p=0.03) and ascites (p=.005), the expression of HIF-1α in SOC was significantly positively correlated with advanced age of the patients (p=0.002), higher grade of the tumor, presence of peritoneal implants (p=0.006), advanced stage of the tumor (p=0.007), presence of distant metastases (p=0.012), peritoneal implants (p=0.044), L.N metastases (p<0.001), and presence of ascites (p=.036).

High Beclin-1 and Low HIF-1α expression were strongly correlated with better response to therapy (p=0.047& 0.022 respectively), increased Chemosensitivity of the tumor (p=0.043& 0.036 respectively), low incidence of recurrence after therapy (p=0.006 & <0.001 respectively), increased the liability of optimal surgical eradication of the tumor, increased 3-year recurrence free overall survival rates (P <0.001). Beclin-1 expression was negatively correlated with HIF-1α expression r correlation coefficient= -0.762 (p<0.001).

Conclusion: Beclin-1 is a marker of good prognosis, while HIF-1α is a marker of poor prognosis in SOC. 

Keywords: Beclin-1; HIF-1α; serous ovarian carcinoma; immunohistochemistry; prognosis

Biography:

Mr. Sourav Taru Saha is a PhD. student working on Breast cancer at the University of the Witwatersrand. The research group’s main focus is the link between Cholesterol and Breast cancer. Till now, his research has shown promising results and in 2018 the concept would be tested in vivo. Based on the results, this research might lead to a novel drug in treating Breast cancer.

Abstract:

Cancer cells have an increased need for cholesterol, which is required for cell membrane integrity. Cholesterol accumulation has been described in various malignancies including breast cancer. Cholesterol has also been known to be the precursor of estrogen and vitamin D, both of which play a key role in the histology of breast cancer. Thus, depleting the cholesterol levels in cancer cells is a proposed innovative strategy to treat cancer. Therefore, novel cholesterol-depleting compounds are currently being investigated. KS-01 is a cyclic amylose oligomer composed of glucose units. It solubilizes the cholesterol and is proven to be toxicologically benign in humans. This led us to hypothesize that it might deplete cholesterol from cancer cells and may prove to be a clinically useful compound. Our work provides preliminary experimental evidences to support this hypothesis.  We identified the potency of KS-01 in vitro against two breast cancer cell lines: MCF-7 (Estrogen positive, ER+), MDA-MB-231(Estrogen negative, ER-) and compared the results against two normal cell lines: MRC-5 (Normal Human Lung Fibroblasts) and HEK-293 (Normal human embryonic kidney cells) using cytotoxic, apoptosis and cholesterol based assays. KS-01 treatment reduced intracellular cholesterol resulting in significant breast cancer cell growth inhibition through apoptosis. The results hold true for both ER+ and ER-. These data suggest that KS-01 can prevent cholesterol accumulation in breast cancer cells and is a promising new anticancer agent.

Biography:

Abstract:

In this work, we demonstrated a ultrasensitive approach for DNA assay base on endonuclease assisted target circle and the hybridization chain reaction (HCR). The dual signal amplification process consists target DNA recognition, nicking enzyme triggered target circle, and hybridization chain reaction. In the presnece of target DNA, the hairpin probe DNA (HP1) was recoginized and partially hybridized with the target to form double-stranded strutures contianing the full recognition sequences for nicking endonuclease. Under the reaction of nicking endonuclease, HP1 was cleavaged into two fragments (trigger DNA and DNA S1) and the target DNA was dissociated from the DNA duplexes. The releasing DNA S1 was able to initiate another endonuclease assisted target circle with the assistance of hairpin probe DNA (HP2). The dissociated target DNA and DNA S1 from the two endonuclease assisted reaction can recognize with other HP1 and HP2 and repeat the hybridiation and cleavage process. Through the ndonuclease assisted cyclical process, a large number of trigger DNA was produced. The resulting trigger DNA can bind to the microplate immobilized capture DNA and the trigger the hybridization chain reaction, resulting in the production of numerous duoble strands DNA with biotin lablling. In the presence of streptavidin conjugated horseradish peroxidase (HRP), the amplified signal can be detected by spectrophotometer via HRP catalyzed substrate 3, 3’ 5, 5’- tetramethylbenzidine (TMB). This proposed signal amplification method provides a detection limit of 0.4 aM, which also exhibits a good linearity ranging from 1 aM to 10 nM.

Biography:

I was born on December 6, 1950 in an area now known as region Dalmatia, currently Split Croatia. I graduated from Split Gymnasium in 1969 with an Associate of Arts Degree in Humanities and Science.

I am US citizen. I have strong Italian ties through my father, Ivo Kostovic who has Italian and Asian origins. He was born on the island of Drvenik-Veli when it was part of region Dalmatia, Italy called Zirona. My mother Bosiljka Rodic Kostovic, with Russian roots, was born in city Omis also originally from Dalmatia region, Italy. Dalmatia was part of Italy for many centuries and currently Dalmatia is located in Croatia Europe.

Abstract:

I, Nick Kostovic, for the first time in recorded history have eliminated magnetic from regular electromagnetic electricity. I also created the next six steps described below. I did this by developing a proprietary way of reversed current RC to create what is bio electricity. The device I created is called the Kostovic BioTechnological Energizer, K-BTE Medical Laser Device

First, my center has successfully developed special current circuit and canceled magnetic from electromagnetic.

Second, this device extracts bio electron photons from H2O electric fluid by wire and wirelessly.

Third, while using the K-BTE device therapist has absolute control of speed/frequency of these released and enriched bio electron photons.

Fourth, bio electrons photons are converted into the strength of Micro or Nano amperes allowing the bio electricity to softly penetrate into the brain or any other physical organ with zero harm to the healthy cells.

Fifth, in the process of extracting bio electron photons from the electric fluid it can include transference of hundreds of different natural acids as well as amino acids. Each biological agent BA is capable to transfer 3 to 6 different natural and amino acids, by enriched bio electron photons.

Sixth, these enriched bio electrons photons are wirelessly transferred through and olive oil coating on the skin enabling the bio electricity to softly penetrate / bio electron photons always penetrate softly on the skin surface/ deeply and efficiently targeting the specific ailing human tissue.

This process is always skillfully directed into the body with the very gentle frequencies of Micro and Nano amperes allowing zero risk of negative consequences.

Note: This is a tentative program and subjected to change time to time basing on the confirmation of speakers.